{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:50:30Z","timestamp":1767984630960,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007699","name":"University of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007699","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PATH Vaccine Solutions, Seattle, WA, USA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.07.107","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T13:00:15Z","timestamp":1501938015000},"page":"5209-5216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines"],"prefix":"10.1016","volume":"35","author":[{"given":"James D.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon O.","family":"Owino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey J.","family":"Crevar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie A.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2017.07.107_b0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2017.07.107_b0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2307\/4575271","article-title":"Public health weekly reports for August 15, 1919. The Epidemiology of influenza","volume":"34","author":"Frost","year":"1919","journal-title":"Public Health Rep"},{"issue":"6088","key":"10.1016\/j.vaccine.2017.07.107_b0015","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"issue":"7403","key":"10.1016\/j.vaccine.2017.07.107_b0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.107_b0025","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/JCM.01279-11","article-title":"Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses","volume":"49","author":"Ducatez","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"21","key":"10.1016\/j.vaccine.2017.07.107_b0030","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1056\/NEJMp068205","article-title":"H5N1 influenza \u2013 continuing evolution and spread","volume":"355","author":"Webster","year":"2006","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2017.07.107_b0035","unstructured":"Organization WH. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines; 2008. <http:\/\/www.who.int\/csr\/disease\/avian influenza\/guidelines\/H5VaccineVirusUpdate20080214.pdf>."},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.107_b0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1089\/aid.2007.0098","article-title":"HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses","volume":"23","author":"Finnefrock","year":"2007","journal-title":"AIDS Res Human Retrov"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.107_b0045","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.03152-15","article-title":"Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses","volume":"90","author":"Carter","year":"2016","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2017.07.107_b0050","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","article-title":"A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.107_b0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/CVI.05533-11","article-title":"Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines","volume":"19","author":"Giles","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.107_b0060","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jis232","article-title":"A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection","volume":"205","author":"Giles","year":"2012","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.107_b0065","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4161\/hv.21265","article-title":"Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6months to 17years of age","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.107_b0070","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2017.07.107_b0075","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.107_b0080","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59((R))-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.107_b0085","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/irv.12031","article-title":"Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy","volume":"7","author":"Fox","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"51","key":"10.1016\/j.vaccine.2017.07.107_b0090","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1016\/j.vaccine.2011.08.089","article-title":"Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions","volume":"29","author":"Fox","year":"2011","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2017.07.107_b0095","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 \u2013 an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.107_b0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4161\/hv.23239","article-title":"Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines","volume":"9","author":"Orsi","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"48","key":"10.1016\/j.vaccine.2017.07.107_b0105","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1016\/j.vaccine.2014.09.049","article-title":"H5N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine","volume":"32","author":"Khurana","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.107_b0110","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/CMR.00005-06","article-title":"Emerging respiratory viruses: challenges and vaccine strategies","volume":"19","author":"Gillim-Ross","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.107_b0115","doi-asserted-by":"crossref","first-page":"e1501","DOI":"10.1371\/journal.pone.0001501","article-title":"Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle","volume":"3","author":"Bright","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.107_b0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vaccine.2014.11.008","article-title":"Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine","volume":"33","author":"Carter","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.107_b0125","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/JVI.02257-12","article-title":"Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus","volume":"87","author":"Carter","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.107_b0130","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/21645515.2015.1012013","article-title":"Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades","volume":"11","author":"Crevar","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.107_b0135","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/JVI.06034-11","article-title":"Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice","volume":"86","author":"Giles","year":"2012","journal-title":"J Virol"},{"issue":"9492","key":"10.1016\/j.vaccine.2017.07.107_b0140","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.107_b0145","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0042-6822(03)00008-4","article-title":"Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine","volume":"308","author":"Bright","year":"2003","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.107_b0150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005\u20132006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2017.07.107_b0155","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0264-410X(02)00539-X","article-title":"Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins","volume":"21","author":"Mitchell","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.107_b0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/77802","article-title":"C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge","volume":"1","author":"Ross","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.07.107_b0165","unstructured":"Askonas B, McMichael A, Webster RG. The immune response to influenza viruses and the problem of protection against infection. In: Beare AS, editor, Basic and applied influenza research. CRC Press; 1982. p. 159\u201388."},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.107_b0170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00037-06","article-title":"Avian influenza virus (H5N1): a threat to human health","volume":"20","author":"Peiris","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.07.107_b0175","doi-asserted-by":"crossref","unstructured":"Torchetti MK et al. Novel H5 clade 2.3.4.4 reassortant (H5N1) virus from a green-winged teal in Washington, USA. Genome Announc 2015;3(2).","DOI":"10.1128\/genomeA.00195-15"},{"issue":"12","key":"10.1016\/j.vaccine.2017.07.107_b0180","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1128\/JVI.00728-15","article-title":"Intercontinental spread of asian-origin H5N8 to North America through Beringia by migratory birds","volume":"89","author":"Lee","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.107_b0185","unstructured":"Jhung MA, Nelson DI, Centers for Disease C, & Prevention. Outbreaks of avian influenza A (H5N2), (H5N8), and (H5N1) among birds \u2013 United States, December 2014-January 2015. MMWR Morb Mortal Wkly Rep 2015;64(4):111."},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.107_b0190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3201\/eid2105.142020","article-title":"Novel Eurasian highly pathogenic avian influenza A H5 viruses in wild birds, Washington, USA, 2014","volume":"21","author":"Ip","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.107_b0195","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4049\/jimmunol.100.5.1139","article-title":"Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man","volume":"100","author":"Davenport","year":"1968","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.107_b0200","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat Biotechnol"},{"issue":"10 Suppl","key":"10.1016\/j.vaccine.2017.07.107_b0205","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/INF.0b013e318168b749","article-title":"Vaccines against pandemic influenza: what can be done before the next pandemic?","volume":"27","author":"Huber","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.07.107_b0210","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.107_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02500-16","article-title":"Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies","volume":"91","author":"Van den Hoecke","year":"2017","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.107_b0220","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/21645515.2015.1111495","article-title":"Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant","volume":"12","author":"Stavaru","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.107_b0225","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.4049\/jimmunol.1600965","article-title":"Low antigen dose in adjuvant-based vaccination selectively induces CD4T cells with enhanced functional avidity and protective efficacy","volume":"198","author":"Billeskov","year":"2017","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.107_b0230","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/21645515.2016.1241360","article-title":"Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB\/c mice","volume":"13","author":"Yam","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.107_b0235","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS One"},{"issue":"43","key":"10.1016\/j.vaccine.2017.07.107_b0240","doi-asserted-by":"crossref","first-page":"17585","DOI":"10.1073\/pnas.1207308109","article-title":"Adjuvant solution for pandemic influenza vaccine production","volume":"109","author":"Clegg","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.107_b0245","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1128\/JVI.01939-10","article-title":"Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets","volume":"85","author":"van den Brand","year":"2011","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T21:37:39Z","timestamp":1692913059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":49,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17310435"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.107","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}